Asia Pacific Melanoma Cancer Diagnostics Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
 Período de previsão |
2024 –2030 |
 Tamanho do mercado (ano base ) | |
 Tamanho do mercado ( Ano de previsão) | USD 1,121.28 |
 CAGR |
% |
| Principais participantes do mercado |
Mercado de diagnóstico de cancro de melanoma Ásia-Pacífico, por tipo de produto (instrumentos, consumíveis e acessórios, entre outros), tipo de teste (teste de biomarcadores, teste de imagem, biópsia, testes de hibridização in situ fluorescente (FISH), testes de hibridização genómica comparativa (CGH), Testes imunohistoquímicos (IHC) e outros), utilizador final (hospitais, laboratórios associados, laboratórios de diagnóstico independentes, centros de diagnóstico por imagem, institutos de investigação do cancro e outros), canal de distribuição (concurso direto e vendas a retalho) - tendências e previsões do setor para 2030.
Análise e insights do mercado de diagnóstico de cancro de melanoma da Ásia-Pacífico
O aumento da procura por métodos de teste não invasivos em todo o mundo aumentou a procura do mercado. O aumento dos gastos em saúde para melhores serviços de saúde está também a contribuir para o crescimento do mercado. Os principais players do mercado estão altamente focados em vários diagnósticos mais rápidos durante este período crucial. Além disso, as iniciativas governamentais para o diagnóstico do cancro do melanoma estão também a contribuir para a crescente procura do mercado de diagnóstico do cancro do melanoma.
As crescentes iniciativas estratégicas de despesas de saúde por parte dos intervenientes no mercado estão a dar oportunidades ao mercado. No entanto, a falta de profissionais qualificados e certificados e o elevado custo dos procedimentos de diagnóstico para os cancros melanoma nas economias emergentes são desafios fundamentais para o crescimento do mercado.
Espera-se que o mercado de diagnóstico de cancro de melanoma da Ásia-Pacífico ganhe crescimento de mercado no período de previsão de 2023 a 2030. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 8,3% no período de previsão de 2023 a 2030 e prevê-se que atinja 1.121,28 milhões de dólares até 2030.
|
Métrica de reporte |
Detalhes |
|
Período de previsão |
2023 a 2030 |
|
Ano base |
2022 |
|
Anos históricos |
2021 (personalizável para 2020-1015) |
|
Unidades Quantitativas |
Receita em milhões de dólares |
|
Segmentos cobertos |
Por tipo de produto (instrumentos, consumíveis e acessórios e outros), tipo de teste (teste de biomarcadores, teste de imagem, biópsia, testes de hibridização fluorescente in situ (FISH), testes de hibridização genómica comparativa (CGH), testes imunohistoquímicos ( IHC) e outros ), Utilizador Final (Hospitais, Laboratórios Associados, Laboratórios de Diagnóstico Independentes, Centros de Diagnóstico por Imagem, Institutos de Investigação do Cancro e Outros), Canal de Distribuição (Concurso Directo e Vendas a Retalho) |
|
Países abrangidos |
China, Japão, Índia, Coreia do Sul, Austrália, Singapura, Tailândia, Malásia, Indonésia, Filipinas, Nova Zelândia, Vietname, Taiwan e resto da Ásia-Pacífico |
|
Participantes do mercado abrangidos |
Nanostring, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Agilent Technologies, Inc, QIAGEN, Inivata Ltd, F. Hoffman-La Roche Ltd, Abbott, AMLo Biosciences Limited, Myriad genetics Genetics Inc, Castle Biosciences, DermTech, Michael Diagnostics Ltd, Damae Medical, Skin Analytics, DermLite, DermaSensor, Skyline Dx, Neracare GmbH, VERISKIN INC., Illumina Inc e bioMerieux SA, entre outros |
Definição de mercado
O diagnóstico do cancro do melanoma é conhecido como o processo de identificação do cancro do melanoma através do estudo das células e moléculas da pele. Estes diagnósticos de cancro melanoma são utilizados como estratégia para pesquisar, analisar e diagnosticar determinadas células ou moléculas com o auxílio de diversos exames realizados em laboratório. É especialmente utilizado para medir um biomarcador específico ou identificar o biomarcador nas células da pele. O diagnóstico de cancro melanoma é utilizado com o objetivo de fornecer testes mais eficientes e diagnósticos mais rápidos.
O diagnóstico do cancro melanoma ajuda os médicos a descobrir os estádios do cancro para tratar eficazmente os doentes em vários estádios. Além disso, com potencial para a prática clínica, são utilizados diversos testes para dar um suporte adicional para aumentar a eficiência no diagnóstico do cancro melanoma, e a presença de grandes players do mercado também contribui para o crescimento do mercado.
Dinâmica do mercado de diagnóstico de cancro de melanoma da Ásia-Pacífico
Motoristas
-
Aumento da procura por diagnóstico precoce de cancro de melanoma
Um cancro potencialmente fatal, os melanomas são encontrados com maior frequência na pele. A incidência de melanoma aumentou significativamente na escala Ásia-Pacífico. A incidência é maior entre as populações de pele clara e em latitudes mais baixas. É um dos cancros com maior número médio de anos perdidos por doença por morte. O melanoma é um grave fardo pessoal e económico devido ao aumento da incidência e mortalidade. Várias áreas de alto risco empregaram medidas preventivas com diferentes graus de sucesso. A génese das doenças e dos factores de risco deve ser melhor compreendida através de iniciativas de investigação.
-
Crescente preferência por exames de saúde preventivos
Os exames de saúde preventivos são ações preventivas realizadas para a deteção inicial do cancro melanoma. Além disso, uma preferência crescente por exames de saúde preventivos proporciona uma salvaguarda contra a provável exposição a qualquer doença no futuro.
A sensibilização para promover o rastreio é a componente mais importante da prevenção do cancro melanoma. O check-up consiste na identificação do cancro e exames de fatores de risco para limitar a perda numa fase inicial.
Oportunidades
-
Aumento dos gastos com a saúde para o tratamento do cancro melanoma
A crescente infra-estrutura de saúde é uma oportunidade para o mercado porque se o investimento em saúde aumentar, mais pessoas ficarão conscientes da doença oncológica e diagnosticarão a sua saúde para precaução e cura.
O aumento dos gastos com a saúde para o tratamento do cancro também ajuda o paciente a fazer um tratamento avançado sem complicações para obter um melhor diagnóstico e tratamento para uma recuperação rápida. Os gastos com a saúde são compostos pela combinação de pagamentos diretos (pessoas que pagam os seus próprios cuidados), despesas governamentais e fontes, incluindo seguros de saúde e atividades de organizações não governamentais. Por causa disso, o aumento dos gastos em saúde para o tratamento do cancro está a funcionar como uma oportunidade para aumentar a procura do mercado.
-
Iniciativas estratégicas de grandes players
As taxas crescentes de vários tipos de doenças e a sua gravidade são amplamente observadas entre as pessoas de todo o mundo. O aumento dramático da qualidade da investigação e o aumento das oportunidades de investigação devem-se a várias iniciativas estratégicas tomadas pelos participantes do mercado. Estão a tomar iniciativas como lançamento de produtos, colaborações, fusões, aquisições e muito mais ao longo dos anos e espera-se que liderem e criem mais oportunidades no mercado. Por exemplo, a Evonik investiu no crescimento a curto prazo da sua produção especializada de diagnósticos de cancro de melanoma nas suas unidades de Hanau e Dossenheim, na Alemanha, que forneceram dois dos quatro diagnósticos de cancro de melanoma para a vacina Pfizer/BioNTech. Segundo Spencer, os primeiros lotes foram entregues à BioNTech em abril de 2021, meses antes do previsto.
Restrições/Desafios
- Regulamentação e normas rigorosas para a aprovação e comercialização de produtos para o diagnóstico de cancro de melanoma
As rigorosas regulamentações para a comercialização de qualquer produto no mercado estão a revelar-se um grande desafio para os fabricantes de produtos de diagnóstico de cancro em todo o mundo, que possuem regulamentos próprios e um organismo diferente para os procedimentos regulamentares.
Aprovação dos fabricantes para comercialização do produto comercializado no mercado. Devido a isto, na região Ásia-Pacífico, espera-se que políticas regulamentares rigorosas dificultem o desenvolvimento do mercado de diagnóstico do cancro.
A exigência regulamentar para aprovações de comercialização ou certificação CE e aplicação de leis e regulamentos pode levar a grandes mudanças nos negócios ou ao pagamento de penalizações, incluindo a potencial perda de licenças comerciais. Os recursos e custos necessários para cumprir estas leis, regras e regulamentos são bastante elevados. Diferentes desafios de fabrico para a produção de nanopartículas lipídicas
Impacto pós-COVID-19 no mercado de diagnóstico do cancro do melanoma da Ásia-Pacífico
O COVID-19 afetou positivamente o mercado. À medida que a procura por diagnósticos aumentava, os exames de saúde preventivos eram muito procurados. Assim, o COVID-19 afetou positivamente o mercado de diagnóstico do cancro do melanoma.
Desenvolvimento recente
- Em outubro de 2022, a Quest Diagnostics Incorporated anunciou que a empresa colaborou com a Decode health para obter dados baseados em biomarcadores que podem ajudar a reduzir o tempo e o custo do desenvolvimento de novos testes de diagnóstico e alvos de medicamentos para diferentes tipos de cancro . Isto ajudará a empresa a encontrar caminhos inovadores na área de I&D e aumentará a presença da empresa na Ásia-Pacífico no mercado
- Em maio de 2022, a Myriad Genetics, Inc. anunciou a expansão da sua parceria estratégica com a Intermountain Precision Genomics, um serviço da Intermountain Healthcare, para adicionar um novo teste de seleção de terapia de biópsia líquida ao crescente portefólio de oncologia da empresa. Isto resulta no aumento do espaço de biópsia líquida para o teste preciso do tumor
Âmbito do mercado de diagnóstico de cancro de melanoma da Ásia-Pacífico
O mercado de diagnóstico de cancro de melanoma da Ásia-Pacífico está segmentado em tipo de produto, tipo de teste, utilizador final e canal de distribuição. O crescimento entre estes segmentos irá ajudá-lo a analisar os escassos segmentos de crescimento nas indústrias e a fornecer aos utilizadores uma valiosa visão geral do mercado e insights de mercado para tomar decisões estratégicas para identificar as principais aplicações do mercado.
Tipo de produto
- Instrumentos
- Consumíveis e acessórios
- Outros
Com base no tipo, o mercado de diagnóstico do cancro do melanoma da Ásia-Pacífico está segmentado em instrumentos, consumíveis e acessórios, entre outros.
Tipo de teste
- Biópsia
- Teste de imagem
- Testes imunohistoquímicos (IHC)
- Teste de biomarcadores
- Testes de hibridização in situ fluorescente (FISH)
- Testes de hibridização genómica comparativa (CGH)
- Outros
Com base no tipo de teste, o mercado de diagnóstico do cancro do melanoma da Ásia-Pacífico está segmentado em teste de biomarcadores, teste de imagem, biópsia, testes de hibridização fluorescente in situ (FISH), testes de hibridização genómica comparativa (CGH) , testes imunohistoquímicos (IHC), entre outros.
Utilizador final
- Hospitais
- Laboratórios associados
- Laboratórios de diagnóstico independentes
- Centros de diagnóstico por imagem
- Institutos de investigação do cancro
- Outros
Com base no utilizador final, o mercado de diagnóstico de cancro de melanoma da Ásia-Pacífico está segmentado em hospitais, laboratórios associados, laboratórios de diagnóstico independentes, centros de diagnóstico por imagem, institutos de investigação do cancro, entre outros.
Canal de Distribuição
- Concurso Direto
- Vendas no Retalho
- Outros
Com base no canal de distribuição, o mercado de diagnóstico do cancro do melanoma da Ásia-Pacífico está segmentado em licitação direta, vendas a retalho, entre outros.
Análise regional/perspetivas do mercado de diagnóstico de cancro de melanoma
O mercado do cancro do melanoma da Ásia-Pacífico é analisado, e os insights e tendências do tamanho do mercado são fornecidos por tipo de produto, tipo de teste, utilizador final e canal de distribuição.
O mercado do cancro do melanoma da Ásia-Pacífico é composto pelos países China, Japão, Índia, Coreia do Sul, Austrália, Singapura, Tailândia, Malásia, Indonésia, Filipinas, Nova Zelândia, Vietname, Taiwan e resto da Ásia-Pacífico.
Espera-se que a Austrália domine o mercado de diagnóstico de cancro de melanoma da Ásia-Pacífico devido à crescente procura de cuidados de saúde de qualidade e à crescente procura de métodos de teste não invasivos que deverão impulsionar o crescimento do mercado.
A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações nas regulamentações do mercado que impactam as tendências atuais e futuras do mercado. Pontos de dados, como vendas de novos e de reposição, demografia do país, epidemiologia de doenças e tarifas de importação e exportação, são alguns dos principais indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas da Ásia-Pacífico e os desafios enfrentados devido à elevada concorrência de marcas locais e nacionais e o impacto dos canais de vendas, ao mesmo tempo que se fornece uma análise de previsão dos dados do país .
Análise do panorama competitivo e da quota de mercado do diagnóstico de cancro de melanoma da Ásia-Pacífico
O panorama competitivo do mercado de diagnóstico de cancro de melanoma da Ásia-Pacífico fornece detalhes dos concorrentes. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença na Ásia-Pacífico, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa, lançamento de produto, largura e amplitude do produto e domínio da aplicação. Os dados acima fornecidos estão apenas relacionados com o foco das empresas no mercado de diagnóstico do cancro do melanoma da Ásia-Pacífico.
Alguns dos principais players que operam no mercado de diagnóstico do cancro do melanoma da Ásia-Pacífico são a Nanostring, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Agilent Technologies, Inc, QIAGEN, Inivata Ltd, F. Hoffman-La Roche Ltd, Abbott , AMLo Biosciences Limited, Myriad genetics Genetics Inc, Castle Biosciences, DermTech, Michael Diagnostics Ltd, Damae Medical, Skin Analytics, DermLite, DermaSensor, Skyline Dx, Neracare GmbH, VERISKIN INC., Illumina Inc e bioMerieux SA, entre outros.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S MODEL
4.2 PORTER'S FIVE FORCES MODEL
5 EPIDEMIOLOGY
6 INDUSTRY INSIGHTS
6.1 DEMOGRAPHIC TRENDS
6.2 KEY PRICING STRATEGIES
6.2.1 PRODUCT INNOVATION
6.2.2 CONSUMER AWARNESS
6.2.3 A VAST NETWORK OF DISTRIBUTION
6.2.4 PARTNERSHIP WITH POPULAR BRANDS BY MAJOR PLAYERS
6.2.5 OTHERS
6.3 KEY PATIENT ENROLLMENT STRATEGIES
6.3.1 IDENTIFICATION OF CUSTOMERS NEED FOR INNOVATIVE DIAGOSTIC PRODUCTS
6.3.2 INCREASING SPECIFIC TACTICS FOR EVERY STEP
6.3.3 EDUCATE AND COMMUNICATE
6.3.4 IMPROVING DIAGNOSIS SEEKING RATE
6.4 INTERVIEWS WITH MANUFACTURING COMPANIES
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 GROWING PREVALENCE OF MELANOMA CANCER
7.1.2 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS
7.1.3 NOVEL TECHNOLOGIES IN MELANOMA CANCER DIAGNOSTICS
7.1.4 INCREASING AWARENESS REGARDING MELANOMA CANCER
7.2 RESTRAINTS
7.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
7.2.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR MELANOMA CANCERS
7.3 OPPORTUNITIES
7.3.1 INCREASING HEALTHCARE EXPENDITURE FOR MELANOMA CANCER TREATMENT
7.3.2 GOVERNMENT INITIATIVES TOWARD MELANOMA CANCER DIAGNOSTICS
7.3.3 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS
7.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE
7.4 CHALLENGES
7.4.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF MELANOMA CANCER DIAGNOSTIC PRODUCTS
7.4.2 RADIATION RISKS FROM IMAGING TESTS
8 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 INSTRUMENTS
8.2.1 IMAGING INSTRUMENTS
8.2.1.1 ULTRASOUND SYSTEMS
8.2.1.2 MRI SYSTEMS
8.2.1.3 CT SYSTEMS
8.2.1.4 OTHERS
8.2.2 BIOPSY INSTRUMENTS
8.2.3 PATHOLOGY-BASED INSTRUMENTS
8.2.3.1 PCR INSTRUMENTS
8.2.3.2 CELL PROCESSORS
8.2.3.3 SLIDE STAINING SYSTEMS
8.2.3.4 TISSUE PROCESSING SYSTEMS
8.2.3.5 OTHER PATHOLOGY-BASED INSTRUMENTS
8.3 CONSUMABLES & ACCESSORIES
8.3.1 KITS
8.3.1.1 PCR KITS
8.3.1.2 NUCLEIC ACID ISOLATION KITS
8.3.1.3 DNA POLYMERASE KITS
8.3.1.4 OTHERS
8.3.2 PROBES
8.3.2.1 Q FISH
8.3.2.2 FLOW FISH
8.3.2.3 OTHERS
8.3.3 REAGENTS
8.3.3.1 ASSAYS
8.3.3.2 BUFFERS
8.3.3.3 PRIMERS
8.3.3.4 OTHERS
8.3.4 OTHER CONSUMABLES
8.4 OTHERS
9 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE
9.1 OVERVIEW
9.2 IMAGING TEST
9.2.1 ULTRASOUND
9.2.2 MRI
9.2.3 CHEST X-RAY
9.2.4 LYMPHOSCINTIGRAPHY
9.2.5 COMPUTED TOMOGRAPHY (CT) SCAN
9.2.6 POSITRON EMISSION TOMOGRAPHY (PET) SCAN
9.2.7 OTHERS
9.3 BIOPSY
9.3.1 OPTICAL BIOPSY
9.3.2 EXCISIONAL BIOPSY
9.3.3 INCISIONAL BIOPSY
9.3.4 SHAVE BIOPSY
9.3.5 PUNCH BIOPSY
9.3.6 OTHERS
9.4 IMMUNOHISTOCHEMICAL (IHC) TESTS
9.4.1 S100 PROTEIN FAMILY BIOPSY
9.4.2 MELAN-A
9.4.3 PMEL/PMEL17/SILV/GP100
9.4.4 TYROSINASE
9.4.5 MITF
9.4.6 SM5-1
9.4.7 CSPG4/HMW-MAA
9.5 BIOMARKER TEST
9.5.1 BRAF MUTATION TEST
9.5.2 NRAS MUTATION TEST
9.5.3 CKIT TEST
9.5.4 OTHERS
9.6 FLUORESCENT IN SITU HYBRIDIZATION (FISH) TESTS
9.7 COMPARATIVE GENOMIC HYBRIDIZATION (CGH) TESTS
9.8 OTHERS
10 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 ASSOCIATED LABS
10.4 DIAGNOSTIC IMAGING CENTERS
10.5 INDEPENDENT DIAGNOSTIC LABORATORIES
10.6 CANCER RESEARCH INSTITUTES
10.7 OTHERS
11 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 DIRECT TENDER
11.3 RETAIL SALES
12 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION
12.1 ASIA-PACIFIC
12.1.1 AUSTRALIA
12.1.2 CHINA
12.1.3 INDIA
12.1.4 NEW ZEALAND
12.1.5 INDONESIA
12.1.6 JAPAN
12.1.7 THAILAND
12.1.8 PHILIPPINES
12.1.9 VIETNAM
12.1.10 MALAYSIA
12.1.11 SOUTH KOREA
12.1.12 SINGAPORE
12.1.13 TAIWAN
12.1.14 REST OF ASIA PACIFIC
13 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 ABBOTT
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 ILLUMINA, INC.
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 BIOMÉRIEUX SA
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENTS
15.4 THERMO FISHER SCIENTIFIC INC.
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.5 F. HOFFMANN-LA ROCHE LTD.
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENT
15.6 AGILENT TECHNOLOGIES, INC.
15.6.1 COMPANY PROFILE
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 AMLO BIOSCIENCES LIMITED
15.7.1 COMPANY PROFILE
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENT
15.8 CASTLE BIOSCIENCES INC
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 DAMAE MEDICAL
15.9.1 COMPANY PROFILE
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENT
15.1 DERMLITE.
15.10.1 COMPANY PROFILE
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENTS
15.11 DERMASENSOR
15.11.1 COMPANY PROFILE
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.12 DERMTECH
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 INIVATA LTD.
15.13.1 COMPANY PROFILE
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 MICHAEL DIAGNOSTICS LTD
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 MYRIAD GENETICS, INC.
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENT
15.16 NANOSTRING
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENT
15.17 NERACARE GMBH
15.17.1 COMPANY PROFILE
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENT
15.18 SKIN ANALYTICS
15.18.1 COMPANY PROFILE
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENT
15.19 SKYLINEDX
15.19.1 COMPANY PROFILE
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENTS
15.2 VERISKIN INC.
15.20.1 COMPANY PROFILE
15.20.2 PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENTS
15.21 QIAGEN
15.21.1 COMPANY SNAPSHOT
15.21.2 REVENUE ANALYSIS
15.21.3 PRODUCT PORTFOLIO
15.21.4 RECENT DEVELOPMENT
15.22 QUEST DIAGNOSTICS INCORPORATED (2022)
15.22.1 COMPANY SNAPSHOT
15.22.2 REVENUE ANALYSIS
15.22.3 PRODUCT PORTFOLIO
15.22.4 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
Lista de Tabela
TABLE 1 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 2 ASIA PACIFIC INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 ASIA PACIFIC INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 4 ASIA PACIFIC IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 5 ASIA PACIFIC PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 6 ASIA PACIFIC CONSUMERS & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 ASIA PACIFIC CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 ASIA PACIFIC KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 9 ASIA PACIFIC PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 10 ASIA PACIFIC REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 11 ASIA PACIFIC OTHERS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 13 ASIA PACIFIC IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 ASIA PACIFIC IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 15 ASIA PACIFIC BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 ASIA PACIFIC BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 17 ASIA PACIFIC IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 ASIA PACIFIC IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 19 ASIA PACIFIC BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 ASIA PACIFIC BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 21 ASIA PACIFIC FLUORESCENT IN SITU HYBRIDIZATION (FISH) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 ASIA PACIFIC COMPARATIVE GENOMIC HYBRIDIZATION (CGH) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 ASIA PACIFIC OTHERS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 25 ASIA PACIFIC HOSPITALS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 ASIA PACIFIC ASSOCIATED LABS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 ASIA PACIFIC DIAGNOSTIC IMAGING CENTERS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 ASIA PACIFIC INDEPENDENT DIAGNOSTIC LABORATORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 ASIA PACIFIC CANCER RESEARCH INSTITUTES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 ASIA PACIFIC OTHERS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 32 ASIA PACIFIC DIRECT TENDER IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 ASIA PACIFIC RETAIL SALES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 35 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 36 ASIA-PACIFIC INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 37 ASIA-PACIFIC PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 38 ASIA-PACIFIC IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 39 ASIA-PACIFIC CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 40 ASIA-PACIFIC KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 41 ASIA-PACIFIC REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 42 ASIA-PACIFIC PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 43 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 44 ASIA-PACIFIC BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 45 ASIA-PACIFIC IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 46 ASIA-PACIFIC BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 47 ASIA-PACIFIC IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 48 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 49 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 50 AUSTRALIA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 51 AUSTRALIA INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 52 AUSTRALIA PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 53 AUSTRALIA IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 54 AUSTRALIA CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 55 AUSTRALIA KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 56 AUSTRALIA REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 57 AUSTRALIA PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 58 AUSTRALIA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 59 AUSTRALIA BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 60 AUSTRALIA IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 61 AUSTRALIA BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 62 AUSTRALIA IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 63 AUSTRALIA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 64 AUSTRALIA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 65 CHINA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 66 CHINA INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 67 CHINA PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 68 CHINA IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 69 CHINA CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 70 CHINA KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 71 CHINA REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 72 CHINA PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 73 CHINA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 74 CHINA BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 75 CHINA IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 76 CHINA BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 77 CHINA IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 78 CHINA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 79 CHINA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 80 INDIA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 81 INDIA INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 82 INDIA PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 83 INDIA IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 84 INDIA CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 85 INDIA KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 86 INDIA REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 87 INDIA PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 88 INDIA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 89 INDIA BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 90 INDIA IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 91 INDIA BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 92 INDIA IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 93 INDIA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 94 INDIA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 95 NEW ZEALAND MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 96 NEW ZEALAND INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 97 NEW ZEALAND PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 98 NEW ZEALAND IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 99 NEW ZEALAND CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 100 NEW ZEALAND KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 101 NEW ZEALAND REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 102 NEW ZEALAND PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 103 NEW ZEALAND MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 104 NEW ZEALAND BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 105 NEW ZEALAND IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 106 NEW ZEALAND BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 107 NEW ZEALAND IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 108 NEW ZEALAND MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 109 NEW ZEALAND MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 110 INDONESIA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 111 INDONESIA INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 112 INDONESIA PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 113 INDONESIA IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 114 INDONESIA CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 115 INDONESIA KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 116 INDONESIA REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 117 INDONESIA PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 118 INDONESIA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 119 INDONESIA BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 120 INDONESIA IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 121 INDONESIA BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 122 INDONESIA IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 123 INDONESIA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 124 INDONESIA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 125 JAPAN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 126 JAPAN INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 127 JAPAN PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 128 JAPAN IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 129 JAPAN CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 130 JAPAN KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 131 JAPAN REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 132 JAPAN PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 133 JAPAN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 134 JAPAN BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 135 JAPAN IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 136 JAPAN BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 137 JAPAN IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 138 JAPAN MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 139 JAPAN MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 140 THAILAND MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 141 THAILAND INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 142 THAILAND PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 143 THAILAND IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 144 THAILAND CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 145 THAILAND KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 146 THAILAND REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 147 THAILAND PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 148 THAILAND MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 149 THAILAND BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 150 THAILAND IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 151 THAILAND BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 152 THAILAND IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 153 THAILAND MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 154 THAILAND MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 155 PHILIPPINES MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 156 PHILIPPINES INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 157 PHILIPPINES PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 158 PHILIPPINES IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 159 PHILIPPINES CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 160 PHILIPPINES KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 161 PHILIPPINES REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 162 PHILIPPINES PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 163 PHILIPPINES MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 164 PHILIPPINES BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 165 PHILIPPINES IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 166 PHILIPPINES BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 167 PHILIPPINES IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 168 PHILIPPINES MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 169 PHILIPPINES MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 170 VIETNAM MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 171 VIETNAM INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 172 VIETNAM PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 173 VIETNAM IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 174 VIETNAM CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 175 VIETNAM KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 176 VIETNAM REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 177 VIETNAM PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 178 VIETNAM MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 179 VIETNAM BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 180 VIETNAM IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 181 VIETNAM BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 182 VIETNAM IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 183 VIETNAM MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 184 VIETNAM MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 185 MALAYSIA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 186 MALAYSIA INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 187 MALAYSIA PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 188 MALAYSIA IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 189 MALAYSIA CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 190 MALAYSIA KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 191 MALAYSIA REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 192 MALAYSIA PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 193 MALAYSIA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 194 MALAYSIA BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 195 MALAYSIA IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 196 MALAYSIA BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 197 MALAYSIA IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 198 MALAYSIA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 199 MALAYSIA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 200 SOUTH KOREA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 201 SOUTH KOREA INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 202 SOUTH KOREA PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 203 SOUTH KOREA IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 204 SOUTH KOREA CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 205 SOUTH KOREA KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 206 SOUTH KOREA REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 207 SOUTH KOREA PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 208 SOUTH KOREA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 209 SOUTH KOREA BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 210 SOUTH KOREA IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 211 SOUTH KOREA BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 212 SOUTH KOREA IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 213 SOUTH KOREA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 214 SOUTH KOREA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 215 SINGAPORE MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 216 SINGAPORE INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 217 SINGAPORE PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 218 SINGAPORE IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 219 SINGAPORE CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 220 SINGAPORE KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 221 SINGAPORE REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 222 SINGAPORE PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 223 SINGAPORE MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 224 SINGAPORE BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 225 SINGAPORE IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 226 SINGAPORE BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 227 SINGAPORE IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 228 SINGAPORE MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 229 SINGAPORE MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 230 TAIWAN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 231 TAIWAN INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 232 TAIWAN PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 233 TAIWAN IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 234 TAIWAN CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 235 TAIWAN KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 236 TAIWAN REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 237 TAIWAN PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 238 TAIWAN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 239 TAIWAN BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 240 TAIWAN IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 241 TAIWAN BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 242 TAIWAN IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 243 TAIWAN MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 244 TAIWAN MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 245 REST OF ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
Lista de Figura
FIGURE 1 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 THE GROWING PREVALENCE OF MELANOMA CANCER AND THE INCREASING AWARENESS REGARDING MELANOMA CANCER ARE EXPECTED TO DRIVE THE ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 ESTIMATED PREVALENCE OF MELANOMA CANCER IN 2020
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET
FIGURE 15 NUMBER OF NEW CASES IN 2018 IN FEMALES OF ALL AGES
FIGURE 16 AGEING EUROPE POPULATION (IN MILLION)
FIGURE 17 ESTIMATED LIFETIME CARE SPENDING
FIGURE 18 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022
FIGURE 19 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 20 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 21 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 22 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022
FIGURE 23 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 24 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 25 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 26 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 27 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 28 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 31 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 32 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 33 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 35 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 36 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 37 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 38 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030)
FIGURE 39 ASIA PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
